Navigation Links
Varian Medical Systems Schedules Fiscal Year End Review for Investors in New York
Date:10/18/2011

PALO ALTO, Calif., Oct. 18, 2011 /PRNewswire/ -- Varian Medical Systems (NYSE: VAR) announced today that its management will hold a fiscal year 2011 review for investors on November 3, 2011 at the Concierge Conference Center, 780 Third Avenue, New York, from 11:30 a.m. ET to 1:00 p.m. ET.

Management will include Tim Guertin, President and CEO; Dow Wilson, Executive Vice President and Chief Operating Officer; Kolleen Kennedy, Senior Vice President and President of Oncology Systems; Robert Kluge, Senior Vice President and President of X-Ray Products; Elisha Finney, Senior Vice President and CFO; Lester Boeh, Vice President Emerging Businesses; and Spencer Sias, Vice President, Investor Relations.

You may RSVP by contacting Anne Rambo at (650) 424-5834, or email: anne.rambo@varian.com.  

The meeting will be webcast and may be accessed via: www.varian.com/investor

Web conferences will be archived on the company website for a year.  Additional information about Varian Medical Systems can be obtained on the company's website.  Investors can subscribe to receive automatic "e-mail alerts" regarding Varian news and events via the company website at www.varian.com/investor.

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximatel
'/>"/>

SOURCE Varian Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
4. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
5. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
6. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
9. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
10. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
11. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015 Tianyin Pharmaceutical Inc. ... that specializes in the development and sale of patented ... and active pharmaceutical ingredients (API) today announced the business ... API operation. 1. Following the September 2014 ...
(Date:1/22/2015)... MINNEAPOLIS, Jan. 22, 2015  Uroplasty, Inc. (NASDAQ: UPI ... markets innovative proprietary products to treat voiding dysfunctions, today ... ended December 31, 2014.  Global revenue for the ... $4.4 million, a new quarterly revenue record, as compared ...
(Date:1/22/2015)... AMGN ) today announced that it will report its ... 27, 2015, after the close of the U.S. financial markets. The ... community at 2 p.m. PT. Participating in the call from Amgen ... officer, and other members of Amgen,s senior management team. ...
Breaking Medicine Technology:TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2
... - First Agent Ever to Demonstrate Significant ... 04, 2007 /PRNewswire-FirstCall/ -- Bayer,HealthCare Pharmaceuticals Inc. ... (sorafenib) tablets significantly,extended overall survival in patients ... versus those taking placebo by 44%,(HR=0.69; p-value=0.0006). ...
... GAITHERSBURG, Md.--(BUSINESS WIRE)--Jun 4, 2007 - GenVec, Inc.,(Nasdaq: ... data from the clinical development program of its ... on,gastrointestinal cancers at the annual meeting of American ... Mitchell Posner, of the,University of Chicago. An oral ...
Cached Medicine Technology:Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 2Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 3Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 4Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 5Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 6Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 7GenVec Announces Update of Safety and Efficacy Data from Pivotal,Phase II/III PACT Study of TNFerade at ASCO 2GenVec Announces Update of Safety and Efficacy Data from Pivotal,Phase II/III PACT Study of TNFerade at ASCO 3GenVec Announces Update of Safety and Efficacy Data from Pivotal,Phase II/III PACT Study of TNFerade at ASCO 4
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining the main ... , Auto insurance quotes help many drivers find the ... to call an agent or visit an agency for price ... website: http://autocarinsurancebest.com/ . , Every business who relies heavily ...
(Date:1/22/2015)... A study recently published in ... Medicine & Science in Sports & Exercise shows ... reduce gastrointestinal (GI) problems associated with physical strain ... the double-blind, placebo-controlled study took 10 grams of ...
(Date:1/22/2015)... Four years since the release of their debut recording Love is ... Avasa & Matthew Love – the duo are pleased to announce ... White Swan Records on February 24, 2015. , THE ROAD offers ... to all of us to walk out of the mire of ...
(Date:1/22/2015)... a famous dress online store for wedding dresses and other ... of wedding dresses , and launches a site-wide women’s dress ... on your big day; the wedding gown is the most ... find the most suitable wedding dress. Now, we are proud ...
(Date:1/22/2015)... State Forestry Institute of Mecklenburg-Vorpommern in ... support from GEOSYSTEMS, a dedicated Hexagon Geospatial and Intergraph ... Hexagon Geospatial’s ERDAS APOLLO for cataloging, managing, ... point clouds and documents. This effort will enable the ...
Breaking Medicine News(10 mins):Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... findings released today indicate that Americans awareness of nanotechnology ... the tiny nanoscale materials and nano-enabled devices and products ... technology that experts believe will usher in a new ... most Americans continue to prefer that government, not industry, ...
... Technologies Inc., a privately,held orthobiologics company, today announced that ... clearance for InQu(TM). InQu is,indicated for use as a ... bone graft,substitute in the extremities and pelvis. InQu ... optimize structural and biological properties to support bone cell,growth. ...
... as depressed, distraught were seldom questioned, study found , , ... disconnect between doctors and some of their neediest patients, ... fail to spot symptoms that raise suicide risk. ... and visit physicians while showing signs of depression or ...
... Cornell University will host more than 200 physicians ... the Northeast Wilderness Medical Conference, Sept. 26-28. Those attending ... by grappling with similar circumstances encountered in the wilderness., ... 11, 2001, disaster in New York City and the ...
... ... Disease, WHITE PLAINS, N.Y., ... with Hodgkin,lymphoma will put the blood cancer in focus. With more than ... awareness about Hodgkin lymphoma and other blood cancers. Hodgkin lymphoma begins ...
... dad in decision-making, researchers say , MONDAY, Sept. 24 (HealthDay ... participate in medical decisions made about their children while in ... parents, published in the October issue of the Journal ... confident talking with doctors, and parents whose child had been ...
Cached Medicine News:Health News:Poll reveals public awareness of nanotech stuck at low level 2Health News:Poll reveals public awareness of nanotech stuck at low level 3Health News:ISTO Technologies Receives 510(k) Clearance for a Novel Bone Graft Substitute and Bone Graft Extender 2Health News:Doctors Often Fail to Spot Suicidal Patients 2Health News:Doctors Often Fail to Spot Suicidal Patients 3Health News:In the Neighborhood: Blood Cancer Strikes Wisteria Lane 2Health News:Most Parents Have Say in Kids' Hospital Care 2
... come back with better resolution, accuracy and ... 25 or 31 rings (same as TMS-1), ... provides high accuracy & repeatability. The small ... & provides extensive corneal coverage. The low ...
... Pachycam is the first compact and ... The OCULUS Pachycam has automatic ... pressure) in accordance with Shah or ... The OCULUS Pachycam is non-contact ...
World's first commercially available vacuum assisted biopsy device for MRI....
... stereotactic, ultrasound and MRI-guided vacuum assisted breast ... Use the patented, FDA-cleared ATEC system for ... advanced method of breast biopsy. Its compassionate ... who trust YOU.,12 Gauge Handpieces: Useful for ...
Medicine Products: